Endothelial progenitor cells (EPCs) are a key cell type present in circulation and are reported to play a role in the development of cardiovascular diseases. EPCs are derived from the bone marrow and mediate the differentiation, regeneration and maintenance of endothelial cells in response to vascular injury and angiogenesis. EPC levels have been proposed as an important biomarker for endothelial dysfunction. However, the association between levels of EPCs and endothelial dysfunction needs further investigation. Cells with the phenotype of CD34+CD133+CD309+ (VEGR2) are defined as “triple positive” circulating EPCs. To evaluate whether EPC levels can be utilized as a smoking-related biomarker of potential harm, we measured triple positive EPC levels by flow cytometer in peripheral blood mononuclear cells (PBMCs) isolated from three different cohorts: healthy smokers (SMK) (n=40), moist snuff consumers (MSC) (n=40) and non-tobacco consumers (NTC) (n=40). We measured total EPC count, EPC percentage and EPC cumulated percentages of triple positive EPCs from the lymphocyte and monocyte populations of SMK, MSC and NTC. All the measurements showed a significant increase in the EPC levels in the SMK cohort compared to NTC. The EPC levels in MSC, however, statistically were not significantly different from SMK or NTC. Higher levels of circulating EPCs in healthy smokers may be due to the increased need to repair vascular wall injury due to cigarette smoking. Further work is needed to establish the role of EPCs in understanding endothelial function and to utilize them as biomarkers of potential harm in tobacco consumers.